Treatment Outcome with Fosravuconazole for Onychomycosis

Fosravuconazole L-lysine ethanolate (F-RVCZ), a ravuconazole prodrug, is newly available agent with high expectations for efficacy in the treatment of onychomycosis. However, clinical data regarding F-RVCZ are limited because drug was launched only Japan 2018. Therefore, we analyzed outcome therapy onychomycosis at outpatient dermatology clinics Japan. We examined 109 patients (68 male, 41 female) varying type, including total dystrophic and dermatophytoma, wide range age groups, elderly. The complete cure rate 12 weeks 6.4% (7/109) 67.9% (74/109) last visit (mean time to visit: 32 ± 14.2 weeks). Mean improvement affected nail area 49.1 23.3% 86.8 22.4% visit. Efficacy visit, respectively, as follows: none, 4 cases 1 case; slight, 35 cases; moderate, 51 21 significant, 9 cure, 7 74 cases. There were no serious adverse events. This retrospective survey first large-scale analysis actual practice outcomes had minimal exclusions. Compared previous reports, our results demonstrated excellent variety patients. Considering ease oral administration (1 capsule/day weeks) few events, appears be useful option